FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
therapy olezarsen as a potential treatment for adults with familial chylomicronemia syndrome (FCS). The FDA granted priority review to this NDA. A filing designated as a priority review reduces the review period by four months. A final decision is expected by Dec 19, 2024. Management has also stated that the FDA does not plan to hold an advisory committee meeting for Ionis' NDA filing. The NDA is supported by results from the phase III BALANCE study, where FCS patients treated with olezarsen achieved significant triglyceride-lowering and substantial reductions in acute pancreatitis attacks in FCS patients. Management is also planning to submit a similar regulatory filing for olezarsen with the EMA later this year. FCS is a rare genetic disease marked by extremely elevated triglyceride levels. People living with this condition are at high risk of acute pancreatitis in addition to other chronic health issues such as fatigue and severe, recurrent abdominal pain. Olezarsen is one
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- She's fighting to stop the brain disease that killed her mother before it gets her. [USA TODAY]USA TODAY
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target raised by analysts at Stifel Nicolaus from $50.00 to $53.00. They now have a "hold" rating on the stock.MarketBeat
- Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock? [Yahoo! Finance]Yahoo! Finance
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed [Yahoo! Finance]Yahoo! Finance
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completedPR Newswire
IONS
Earnings
- 5/7/24 - Beat
IONS
Sec Filings
- 6/20/24 - Form 4
- 6/18/24 - Form 8-K
- 6/17/24 - Form 144
- IONS's page on the SEC website